中信建投（601066）此前指出，公司是国内外周介入和神经介入行业的龙头企业，产品管线丰富，更有 多款创新产品有望陆续获批，在部分产品有望受益集采、进口替代加速的背景下，公司内生业务有望保 持快速增长。2024年公司首次实现扭亏为盈，随着公司销售规模的持续扩大，叠加公司管理经营效率的 持续改善，公司盈利能力有望持续提升。公司在手资金充裕，截至25H1，公司在手现金为25.3亿元，预 计公司将继续加大产品研发和学术推广力度，并寻求外延并购及对外合作的机会，不断稳固公司行业龙 头的地位。 消息面上，本月初，归创通桥旗下归创医疗自主研发的ZYLOX KINGKONG金刚外周高压球囊扩张导 管经过国家药品监督管理局审查批准，正式获批上市。该产品适用于包括上肢、肾、髂和腹股沟下血管 在内的周围血管的经皮腔内血管成形术，以及治疗自体或人造透析用动静脉痿的狭窄，也适用于外周血 管系统中的支架和覆膜支架的后扩张。 归创通桥(02190)盘中涨超5%，截至发稿，涨3.76%，报23.2港元，成交额1539.07万港元。 ...

U.S. stocks were lower, with the Dow Jones index falling around 0.1% on Tuesday.Shares of Novo Nordisk A/S (NYSE:NVO) rose sharply during Tuesday's session following FDA approval of its Wegovy pill.Novo Nordisk received approval from the U.S. Food and Drug Administration for its GLP-1 pill, marking the first approval of its kind globally.Novo Nordisk shares jumped 8.6% to $52.26 on Tuesday.Here are some other big stocks recording gains in today’s session.WW International Inc (NASDAQ:WW) shares jumped 14.4% ...

Investment Rating - The investment rating for the company is "Buy" with a market price of RMB 108.83 and a sector rating of "Outperform" [1][5]. Core Insights - The company reported a revenue of RMB 382 million for the first three quarters of the year, representing a year-on-year growth of 30.58%. The net profit attributable to the parent company was RMB 93 million, up 57.93% year-on-year [5]. - The third quarter revenue was RMB 134 million, showing a year-on-year increase of 31.54%, while the net profit decreased by 9.39% year-on-year [5]. - The company is expected to continue launching new products, which will contribute to future growth, maintaining a positive outlook for the company's development [5][7]. Financial Performance Summary - For the years 2023 to 2027, the company is projected to achieve the following: - Revenue growth rates of 25.6% in 2023, 35.4% in 2024, and 37.5% in 2025 [9]. - Net profit growth rates of 21.1% in 2023, 27.0% in 2024, and 60.8% in 2025 [9]. - The estimated earnings per share (EPS) are expected to rise from RMB 0.84 in 2023 to RMB 3.27 in 2027 [9]. - The company maintains a high R&D expense ratio, with R&D expenses accounting for 30.81% of revenue in the first three quarters [10]. Product Development and Market Position - The company is in the process of launching multiple new products, with 8 products currently in the registration review phase [10]. - The collagen product line, particularly Collagen-I, is nearing approval and is expected to provide significant revenue growth [10].

Core Viewpoint - The company has received approval for its feed additive product, red yeast, which is expected to enhance its product portfolio and competitiveness, although it is not anticipated to have a significant impact on this year's performance [1] Group 1: Product Approval - The company has obtained the product approval number for its feed additive red yeast from the Inner Mongolia Agricultural and Animal Husbandry Department, with the approval date set for September 15, 2025 [1] - The approval number is 蒙饲添字（2025）090001, indicating regulatory compliance for the new product [1] Group 2: Production Capacity - The company has established a production project with an annual capacity of 3,000 tons for astaxanthin, a metabolite of red yeast [1] - This production capacity is expected to support the company's growth and diversification in its product offerings [1] Group 3: Financial Impact - The approval of the new product is expected to enrich the company's product structure and enhance its competitiveness [1] - However, it is noted that the approval will not have a major impact on the company's performance for the current fiscal year [1]

Core Viewpoint - The approval of hydrochlorothiazide as a chemical raw material drug by the National Medical Products Administration enhances the company's product portfolio and strengthens its market competitiveness, positively impacting future operating performance [1] Group 1 - The company received the approval notice for hydrochlorothiazide from the National Medical Products Administration [1] - The application for the domestic production of hydrochlorothiazide was submitted in April 2024 and accepted by the Center for Drug Evaluation [1] - The company completed supplementary research and submitted the required documentation by May 2025, leading to the approval in August 2025 [1] Group 2 - Hydrochlorothiazide is indicated for conditions such as edema, hypertension, central or nephrogenic diabetes insipidus, and nephrolithiasis [1] - The approval of this product enriches the company's product categories and improves its full industry chain layout [1] - The new product is expected to have a positive impact on the company's future operating performance [1]